Literature DB >> 9018146

Sequence close to the N-terminus of L2 protein is displayed on the surface of bovine papillomavirus type 1 virions.

W J Liu1, L Gissmann, X Y Sun, A Kanjanahaluethai, M Müller, J Doorbar, J Zhou.   

Abstract

The bovine papillomavirus type 1 (BPV1) L2 protein purified from Escherichia coli was used as an antigen to produce monoclonal antibodies (MAbs). A total of 26 individual clones which recognized the BPV1 L2 protein were obtained. Using infectious BPV1 virus particles, 3 of the MAbs were found to interact with BPV1 virus particles. Binding of the MAbs to BPV1 was confirmed by immunoelectron microscopy. A set of 92 13-mer peptides overlapping by 8 amino acids spanning the entire BPV1 L2 protein was synthesized on a membrane and used to map the epitopes recognized by these antibodies. Seventeen linear epitopes were identified. Our results revealed that a sequence toward the N-terminus of the L2 protein (aa 61-123) is displayed on the virus surface, while the remaining L2 sequences are hidden inside the virus capsid. Although the polyclonal antisera raised against BPV1 L2 neutralized the BPV1 virus, we failed to detect any neutralizing activity for the 3 L2-specific monoclonal antibodies which bound to the BPV1 particles. This suggests that extra binding sites may be needed for neutralization. This study prompted us to propose a model about how L1 and L2 proteins may interact during infectious papillomavirus assembly.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9018146     DOI: 10.1006/viro.1996.8348

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  42 in total

1.  Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection.

Authors:  R B Roden; P M Day; B K Bronzo; W H Yutzy; Y Yang; D R Lowy; J T Schiller
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

2.  A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes.

Authors:  Nadine Kämper; Patricia M Day; Thorsten Nowak; Hans-Christoph Selinka; Luise Florin; Jan Bolscher; Lydia Hilbig; John T Schiller; Martin Sapp
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection.

Authors:  Rebecca M Richards; Douglas R Lowy; John T Schiller; Patricia M Day
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

4.  Human Papillomavirus Major Capsid Protein L1 Remains Associated with the Incoming Viral Genome throughout the Entry Process.

Authors:  Stephen DiGiuseppe; Malgorzata Bienkowska-Haba; Lucile G M Guion; Timothy R Keiffer; Martin Sapp
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

5.  Bovine papillomavirus type 1 infection is mediated by SNARE syntaxin 18.

Authors:  Valerie Laniosz; Kha C Nguyen; Patricio I Meneses
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

Review 6.  Papillomavirus prophylactic vaccines: established successes, new approaches.

Authors:  M Saveria Campo; Richard B S Roden
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

7.  Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression.

Authors:  Patricia M Day; Carl C Baker; Douglas R Lowy; John T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-21       Impact factor: 11.205

8.  Construction and production of fluorescent papillomavirus-like particles.

Authors:  S Peng; J Zhou; I H Frazer
Journal:  J Tongji Med Univ       Date:  1999

9.  Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein.

Authors:  Monica E Embers; Lynn R Budgeon; Martin Pickel; Neil D Christensen
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Target cell cyclophilins facilitate human papillomavirus type 16 infection.

Authors:  Malgorzata Bienkowska-Haba; Hetalkumar D Patel; Martin Sapp
Journal:  PLoS Pathog       Date:  2009-07-24       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.